ReviewJournal of thoracic disease2019
House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis.
Review in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Efficacy and safety of allergen-specific immunotherapy for allergic asthma: a meta-analysis comparing sublingual and subcutaneous routes across allergen types and age groups.Annals of medicine · 2026Pooled it
- Serum metabolomic profiling identifies taurolithocholic acid as a predictor of HDM-SCIT response in allergic rhinitis: clinical discovery and experimental validation.Frontiers in immunology · 2026Article
- Small airway impairment and bronchial hyperreactivity in patients with house dust mites-allergic rhinitis.Asia Pacific allergy · 2025Article
- Design and Development of an Electronic Platform for Allergen Immunotherapy in China.International journal of telemedicine and applications · 2025Article
- A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis.Immunotherapy · 2024Article
- Clinical and experimental treatment of allergic asthma with an emphasis on allergen immunotherapy and its mechanisms.Clinical and experimental immunology · 2023Article
- Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.Allergy, asthma & immunology research · 2022Review
- Febuxostat Alleviates Allergic Rhinitis by Inhibiting Inflammation and Monocyte Adhesion in Human Nasal Epithelial Cells via Regulating KLF6.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- [The secondary prevention effect and influence on serum sIgG4, IL-27 and IL-33 levels of subcutaneous immunotherapy in children with allergic rhinitis and cough variant asthma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of allergen immunotherapy (AIT) has been reported with different allergens including house dust mites (HDM). HDM are the most prevalent allergens in patients with asthma and/or rhinitis in China. In addition to improving symptoms, reducing medication need, and improving quality of life, AIT can change the course of allergic disease and induce allergen-specific immune tolerance. To date, the use of AIT is becoming more acceptable in China, and there are many studies about the current clinical practice immunotherapy. In this paper we discuss the main aspects of AIT undertaken in China; including symptom and medication scores, pulmonary function and airway hyperresponsiveness, specific allergen sensitivity, safety evaluation, and mechanisms underlying AIT. This review will provide some important information on AIT treatment strategies to doctors, healthcare professionals and organizations involved in the AIT in China. According to the studies in China, successful AIT may induce antibody responses and cellular reactions in relation to the significant improvement in clinical symptoms, reducing the need for medications and maintenance of stable pulmonary functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.